Antibe Therapeutics Inc(Pre-Merger) ATBPF

PH2 Liver transient elevatisame as you guessed it nasaids...

[WalkOverTheStrt]

https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14641

3.7 Liver-related effects

Blood levels of liver enzymes (including alanine transaminase and aspartate transaminase) were measured on Days 7 and 14 of treatment and at 2 weeks post-treatment (Day 28). Over the 14-day treatment period, clinically insignificant, treatment-related transient elevations in liver transaminases were observed in 7% of subjects receiving ATB-346 and 7% of subjects receiving naproxen.
One subject receiving ATB-346 had clinically significant, treatment-related, transient transaminase elevations during this period. At the 2-week post-treatment assessment, 5.4% of the ATB-346-treated subjects had clinically significant, treatment-related, transient transaminase elevations that had resolved or were resolving. Cumulative data from the three clinical trials in which ATB-346 has been administered at 250 mg once daily for 10–14 days reveal a 4.7% overall incidence of clinically significant increases in liver transaminases. This is comparable to what has been observed with the use of NSAIDs such as diclofenac, naproxen, and piroxicam (~4%) and well below that observed with acetaminophen (39%; National Institute of Health, n.d.). One naproxen-treated subject had clinically significant elevations of alkaline phosphatase and total bilirubin at the end of treatment (Day 14).

[Amigo11]

WOTS -thanks for this -very interesting

[IrishCanuck]

For all the flack management got for not "juicing" the share price from overhyping they should be respected for their message still remaining intact.  They always said it wasn't about being superior pain relief, we just had to not be inferior. The same should be said for aminotransferases, we shouldn't HAVE to be lower than the rest of NSAID class we should just be

[WalkOverTheStrt]

IrishCanuck  -solid points and hopefully Candad Health and FDA see it the same way.  Do you think Antibe will try to accelerate 352 to humans (right now 2022 no qtr date) to help support the stock price and strive for early human results in 2022? Are you expecting data analysis to be completed by Antibe in the coming weeks or are you expecting multiple months? 

[IrishCanuck]

I thought they were already planning to fast-track 352 and it was supposed to be Q1, but now we won't know prioritization for a while or if any delays occur. If they can keep up with the animal toxicology I don't see why they wouldn't try doing that. But we'll see...   

[WalkOverTheStrt]

Thanks, last I saw was corp deck slide 23 "Currently in IND-enabling studies — human trials slated for 2022" pretty vague but Ill need to listen to the last conference / presentation they gave https://secureservercdn.net/72.167.241.46/ln9.cea.myftpupload.com/wp-content/uploads/2021/07/Antibe-Corporate-Presentation-July-2021.pdf

[Amigo11]

I see they are presenting Thursday-maybe this will get answered.Good to see management getting in front of money quickly after "the Pause".